The American Gastroenterological Association (AGA) has released a new clinical guideline on the pharmacological management of moderate-to-severe ulcerative colitis, published in Gastroenterology. This ...

June 15 (Reuters) - Spyre Therapeutics said on Monday its experimental bowel disease drug met the main goal of significantly ...

ulcerative colitis, inflammatory bowel disease, IBD, UC Researchers performed a systematic review of clinical trials to assess the need for a consensus on the definition of mild to moderate, active ...

Etrasimod, an investigational selective sphingosine 1-phosphate (S1P) receptor modulator, led to clinically meaningful improvements in patients with moderately to severely active ulcerative colitis ...

The treatment showed strong and lasting benefits in 580 adults with moderate to severe ulcerative colitis in the maintenance trial. ・Both the 25 mg and 50 mg doses achieved the main goal of clinical ...

AGA living guideline recommends patients start advanced therapies early in their disease course rather than gradual step-up treatment approach. “Since the first biologic treatment for ulcerative ...

Omvoh is a biologic medicine used to treat moderate to severe ulcerative colitis. Ulcerative colitis is an inflammatory bowel disease that causes inflammation in parts of the digestive tract. Common ...

The U.S. Food and Drug Administration has approved Velsipity (etrasimod) for adults with moderately to severely active ulcerative colitis (UC). The approval was based on results from the ELEVATE UC ...

LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe ...

Ferring Pharmaceuticals today announces results from the OPTIMISE study showing the first real-world evidence of the effectiveness of a treat-to-target (T2T) approach based on faecal calprotectin (FC) ...